| Identifier |
20230315_nanos_neuroimmunology1_05 |
| Title |
Good Therapies Gone Bad - What the Neuro-Ophthalmologist Needs to Know |
| Creator |
Fiona Costello, MD, FRCP |
| Affiliation |
Professor, Departments of Clinical Neurosciences and Surgery, Associate Dean of Chairs and Professorships, Cumming School of Medicine, University of Calgary, Calgary, Alberta |
| Subject |
Disease Modifying Treatments (DMTs); Progressive Multifocal Leukoencephalopathy (PML); Immune Check Point Inhibitors; Tumor Necrosis Factor (TNF)-a Inhibitors; Immune Reconstitution Inflammatory Reaction (IRIS) |
| Description |
The discovery of targeted immunotherapies has changed the clinical course and long term prognosis for people living with a variety of conditions including neuromuscular diseases, inflammatory disorders of the central nervous system (CNS), and specific cancers. While many of these therapies have advanced the care of our patients, their use may sometimes lead to deleterious side effects. This presentation will highlight complications of immunotherapies relevant to Neuro-ophthalmic practice. |
| Date |
2023-03 |
| References |
1. Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012. PMID: 33375365; PMCID: PMC7823546. 2. Shah AA, Corboy JR. Discontinuing Disease-Modifying Therapies in Multiple Sclerosis. Practical Neurology. https://practicalneurology.com/articles/2022-feb/discontinuing-disease-modifyingtherapies-in-multiple-sclerosis (Accessed December 11, 2022). 3. Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Current Neurology and Neuroscience Reports. 2021; 21:36 https://doi.org/10.1007/s11910-021-01117-y. 4. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017; 264:2351-2374. 5. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Sevennignsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77(2):184-191. doi:10.1001/jamaneurol.2019.3365. |
| Language |
eng |
| Format |
application/pdf |
| Format Creation |
Microsoft PowerPoint |
| Type |
Text |
| Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2023: Neuroimmunology: https://novel.utah.edu/collection/NAM/toc/ |
| Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
| Publisher |
North American Neuro-Ophthalmology Society |
| Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6cgj7vk |
| Setname |
ehsl_novel_nam |
| ID |
2386614 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6cgj7vk |
